Search

Your search keyword '"Ullmann, Andrew"' showing total 426 results
Start Over Author "Ullmann, Andrew"
426 results on '"Ullmann, Andrew"'

54. Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Ruhnke, Markus, primary, Cornely, Oliver A., additional, Schmidt‐Hieber, Martin, additional, Alakel, Nael, additional, Boell, Boris, additional, Buchheidt, Dieter, additional, Christopeit, Maximilian, additional, Hasenkamp, Justin, additional, Heinz, Werner J., additional, Hentrich, Marcus, additional, Karthaus, Meinolf, additional, Koldehoff, Michael, additional, Maschmeyer, Georg, additional, Panse, Jens, additional, Penack, Olaf, additional, Schleicher, Jan, additional, Teschner, Daniel, additional, Ullmann, Andrew John, additional, Vehreschild, Maria, additional, Lilienfeld‐Toal, Marie, additional, Weissinger, Florian, additional, and Schwartz, Stefan, additional

Published
2020
Full Text
View/download PDF

56. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT

Author

Schmidt-Hieber, Martin, primary, Engelhard, Dan, additional, Ullmann, Andrew, additional, Ljungman, Per, additional, Maertens, Johan, additional, Martino, Rodrigo, additional, Rovira, Montserrat, additional, Shaw, Peter J., additional, Robin, Christine, additional, Faraci, Maura, additional, Byrne, Jenny, additional, Schäfer-Eckart, Kerstin, additional, Einsele, Hermann, additional, Faber, Edgar, additional, Rigacci, Luigi, additional, Saccardi, Riccardo, additional, Balaguer-Rosello, Aitana, additional, Isaksson, Cecilia, additional, Christopeit, Maximilian, additional, Tridello, Gloria, additional, Wang, Junfeng, additional, Knelange, Nina, additional, Mikulska, Malgorzata, additional, Cesaro, Simone, additional, and Styczynski, Jan, additional

Published
2019
Full Text
View/download PDF

57. Posaconazole concentrations in the central nervous system

Author

Rüping, Maria J. G. T., Albermann, Nadine, Ebinger, Friedrich, Burckhardt, Irene, Beisel, Claudia, Müller, Carsten, Vehreschild, Jörg J., Kochanek, Matthias, Fätkenheuer, Gerd, Bangard, Christopher, Ullmann, Andrew J., Herr, Wolfgang, Kolbe, Karin, Hallek, Michael, and Cornely, Oliver A.

Published
2008

59. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis

Author

Cornely, Oliver A., Böhme, Angelika, Reichert, Dietmar, Reuter, Stefan, Maschmeyer, Georg, Maertens, Johan, Buchheidt, Dieter, Paluszewska, Monika, Arenz, Dorothee, Bethe, Ullrich, Effelsberg, Jenny, Lövenich, Harry, Sieniawski, Michal, Haas, Antje, Einsele, Hermann, Eimermacher, Hartmut, Martino, Rodrigo, Silling, Gerda, Hahn, Moritz, Wacker, Sidonie, Ullmann, Andrew J., and Karthaus, Meinolf

Published
2008

60. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Schweizerische Gesellschaft Für Hämatologie, Maschmeyer, Georg, Lilienfeld-Toal, Marie Von, Schweizerische Gesellschaft Für Medizinische Onkologie, Silling, Gerda, Sandherr, Michael, Wolf, Hans-Heinrich, Liss, Blasius Janusch, Buchheidt, Dieter, Egerer, Gerlinde, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Cornely, Oliver Andreas, Rieger, Christina Theresa, Hentrich, Marcus, Vehreschild, Maria J. G. T., Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Ullmann, Andrew, Lehners, Nicola, Heinz, Werner, Mayer, Karin Tina, and Mellinghoff, Sibylle Christiane

Subjects
Medizin und Gesundheit
Published
2019
Full Text
View/download PDF

61. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Karthaus, Meinolf, Penack, Olaf, Ritter, Jörg, Kurzai, Oliver, Maschmeyer, Georg, Lilienfeld-Toal, Marie Von, Schweizerische Gesellschaft Für Medizinische Onkologie, Schmidt-Hieber, Martin, Buchheidt, Dieter, Rieger, Christina Theresa, Schwartz, Stefan, Rickerts, Volker, Hamprecht, Axel, Heinz, Werner, Schuelper, Nikolai, Schweizerische Gesellschaft Für Hämatologie, Weber, Thomas, Wolf, Hans-Heinrich, Vehreschild, Jörg Janne, Horger, Marius Stefan, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Heußel, Claus Peter, Deutsche Gesellschaft Für Hämatologie Und Onkologie. Arbeitsgemeinschaft Infektiologie, Löffler, Jürgen, Christopeit, Maximilian Erich Joachim, Ruhnke, Markus, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Behre, Gerhard, and Ullmann, Andrew

Subjects
Medizin und Gesundheit
Published
2019
Full Text
View/download PDF

67. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia

Author

Glasmacher, Axel, Cornely, Oliver, Ullmann, Andrew J., Wedding, Ulrich, Bodenstein, Heinrich, Wandt, Hannes, Boewer, Christian, Pasold, Rita, Wolf, Hans-Heinrich, Hänel, Mathias, Dölken, Gottfried, Junghanss, Christian, Andreesen, Reinhard, and Bertz, Hartmut

Published
2006

69. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study

Author

Hess, Georg, Bunjes, Donald, Siegert, Wolfgang, Schwerdtfeger, Rainer, Ledderose, Georg, Wassmann, Barbara, Kobbe, Guido, Bornhäuser, Martin, Hochhaus, Andreas, Ullmann, Andrew J., Kindler, Thomas, Haus, Ulrike, Gschaidmeier, Harald, Huber, Christoph, and Fischer, Thomas

Published
2005
Full Text
View/download PDF

71. Treatment of fungal infections in hematology and oncology

Author

Böhme, Angelika, Ruhnke, Markus, Buchheidt, Dieter, Karthaus, Meinolf, Einsele, Hermann, Guth, Stefan, Heussel, Gudrun, Heussel, Claus-Peter, Junghanss, Christian, Kern, Winfried K., Kubin, Thomas, Maschmeyer, Georg, Sezer, Orhan, Silling, Gerda, Südhoff, Thomas, Szelényi, Hubert, and Ullmann, Andrew J.

Published
2003
Full Text
View/download PDF

74. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

Author

Penack, Olaf, Schweizerische Gesellschaft Für Hämatologie, Kalkreuth, Jana, Lilienfeld-Toal, Marie Von, Maschmeyer, Georg, Weber, Thomas, Klein, Michael, Schweizerische Gesellschaft Für Medizinische Onkologie, Silling, Gerda, Kochanek, Matthias, Wolf, Hans-Heinrich, Hauf, Elke, Schalk, Enrico, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Berger, Annemarie, Heußel, Claus Peter, Rieger, Christina Theresa, Christopeit, Maximilian Erich Joachim, Hentrich, Marcus, Vehreschild, Maria J. G. T., Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Lehners, Nicola, Ullmann, Andrew, and Mayer, Karin Tina

Subjects
Medizin und Gesundheit
Published
2018
Full Text
View/download PDF

76. Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis

Author

Belic, Stanislav, primary, Page, Lukas, additional, Lazariotou, Maria, additional, Waaga-Gasser, Ana Maria, additional, Dragan, Mariola, additional, Springer, Jan, additional, Loeffler, Juergen, additional, Morton, Charles Oliver, additional, Einsele, Hermann, additional, Ullmann, Andrew J., additional, and Wurster, Sebastian, additional

Published
2019
Full Text
View/download PDF

77. Additional file 1: of Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals

Author

Biehl, Lena, Bertz, Hartmut, Bogner, Johannes, Ute-Helke Dobermann, Kessel, Johanna, Krämer, Carolin, Lemmen, Sebastian, Lilienfeld-Toal, Marie Von, Peter, Silke, Pletz, Mathias, Rohde, Holger, Schmiedel, Stefan, Schubert, Sören, Ullmann, Andrew, Fätkenheuer, Gerd, and Vehreschild, Maria

Abstract

English language print-version of survey. (PDF 123 kb)

Published
2017
Full Text
View/download PDF

78. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells.

Author

Weis, Philipp, Helm, Johanna, Page, Lukas, Lauruschkat, Chris D, Lazariotou, Maria, Einsele, Hermann, Loeffler, Juergen, Ullmann, Andrew J, and Wurster, Sebastian

Abstract

CD154+ mould-reactive T cells were proposed as a novel biomarker in the diagnosis of invasive mycoses. As PBMC-based protocols for flow cytometric quantification of these cells are logistically challenging and susceptible to preanalytic delays, this study evaluated and optimized a whole blood-based method for the detection of mould-reactive T cells. Blood collection tubes containing costimulatory antibodies and Aspergillus fumigatus mycelial lysates were inoculated with heparinized whole blood from healthy adults, and detection rates of CD154+/CD4+ A. fumigatus reactive T cells were compared with PBMC-based detection using samples from the same donors. In contrast to the PBMC-based method, double costimulation with αCD28 and αCD49d was crucial for reliable whole blood stimulation. Optimizing stimulation schemes for both matrixes, significantly higher specific T-cell detection rates were achieved by the whole blood-based method, whereas the unspecific background stimulation remained low. MHC II-dependent CD154+ upregulation was demonstrated for both matrixes. Excellent correlation and reproducible conversion factors between whole blood and PBMC-based results were observed. Using frozen ready-to-use test tubes containing costimulatory antibodies and lysates, detection rates of specific T cells were comparable to freshly prepared blood collection tubes. The optimized whole blood-based protocol was also used to detect Rhizopus arrhizus and Rhizomucor pusillus reactive T cells, resulting in 1.5- to 2.7-fold higher detection rates compared with PBMC-based measurement. In summary, the whole blood protocol is a robust, highly sensitive, and cost-effective method for mould-reactive T-cell quantification, allowing for point-of-care sample stimulation and contributing to better assay standardization in multi-centre evaluation of mould reactive T-cell quantification. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

79. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)

Author

Ruhnke, Markus, primary, Behre, Gerhard, additional, Buchheidt, Dieter, additional, Christopeit, Maximilian, additional, Hamprecht, Axel, additional, Heinz, Werner, additional, Heussel, Claus-Peter, additional, Horger, Marius, additional, Kurzai, Oliver, additional, Karthaus, Meinolf, additional, Löffler, Jürgen, additional, Maschmeyer, Georg, additional, Penack, Olaf, additional, Rieger, Christina, additional, Rickerts, Volker, additional, Ritter, Jörg, additional, Schmidt-Hieber, Martin, additional, Schuelper, Nikolai, additional, Schwartz, Stefan, additional, Ullmann, Andrew, additional, Vehreschild, Jörg Janne, additional, von Lilienfeld-Toal, Marie, additional, Weber, Thomas, additional, and Wolf, Hans H., additional

Published
2018
Full Text
View/download PDF

80. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole

Author

Maertens, Johan, primary, Selleslag, Dominik, additional, Heinz, Werner J., additional, Saulay, Mikael, additional, Rahav, Galia, additional, Giladi, Michael, additional, Aoun, Mickael, additional, Kovanda, Laura, additional, Kaufhold, Achim, additional, Engelhardt, Marc, additional, Cornely, Oliver A., additional, Herbrecht, Raoul, additional, and Ullmann, Andrew J., additional

Published
2018
Full Text
View/download PDF

83. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

Author

Cornely, Oliver A, primary, Robertson, Michael N, additional, Haider, Shariq, additional, Grigg, Andrew, additional, Geddes, Michelle, additional, Aoun, Mickael, additional, Heinz, Werner J, additional, Raad, Issam, additional, Schanz, Urs, additional, Meyer, Ralf G, additional, Hammond, Sarah P, additional, Mullane, Kathleen M, additional, Ostermann, Helmut, additional, Ullmann, Andrew J, additional, Zimmerli, Stefan, additional, Van Iersel, M L P S, additional, Hepler, Deborah A, additional, Waskin, Hetty, additional, Kartsonis, Nicholas A, additional, and Maertens, Johan, additional

Published
2017
Full Text
View/download PDF

84. Stellungnahme zur Nutzenbewertung des IQWiG gemäß § 35a SGB V, Vorgangsnummer 2015-11-15-D-192, G-BA Bericht, veröffentlicht am 15. Februar 2016, IQWiG Bericht Nr. 360, veröffentlicht am 2. Februar 2016

Author

Mousset, Sabine, Ostermann, Helmut, Maschmeyer, Georg, Wörmann, Bernhard, Cornely, Oliver Andreas, Deutsche Krebsgesellschaft. Arbeitsgemeinschaft Für Internistische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, Ullmann, Andrew, and Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie. Arbeitsgemeinschaft Für Internistische Onkologie

Subjects
Medizin und Gesundheit
Published
2016
Full Text
View/download PDF

85. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Author

Denning, David W., Cadranel, Jacques, Beigelman-Aubry, Catherine, Ader, Florence, Chakrabarti, Arunaloke, Blot, Stijn, Ullmann, Andrew J., Dimopoulos, George, Lange, Christoph, Microbiology, European Society, Diseases, Infectious, Society, European Respiratory, The National Aspergillosis Centre, Wythenshawe Hospital-University Hospital of South Manchester, Service de Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Departement de radiologie médicale [Lausanne], Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Pathogenèse des légionelles- Legionella pathogenesis (LegioPath), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Postgraduate Institute of Medical Education and Research, University of Queensland [Brisbane], University Hospital of Würzburg, 'Attikon' University Hospital, German Centre for Infection Research (DZIF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Hemoptysis, Antifungal Agents, Bronchial Arteries, Aspergillosis, Antifibrinolytic agent, Amphotericin B, Tomography, Lung, Invasive Pulmonary Aspergillosis, Thoracic Surgery, Video-Assisted, Chronic pulmonary aspergillosis, Thoracic Surgery, Disease Management, Embolization, Therapeutic, Antifibrinolytic Agents, 3. Good health, X-Ray Computed, medicine.anatomical_structure, Tranexamic Acid, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Allergic bronchopulmonary aspergillosis, Therapeutic, Bronchial artery, Immunocompetence, Aspergilloma, medicine.drug, Pulmonary and Respiratory Medicine, medicine.medical_specialty, 030106 microbiology, Video-Assisted, 03 medical and health sciences, Embolization, Immunocompromised Host, medicine.artery, Internal medicine, Bronchoscopy, medicine, Humans, business.industry, Aspergillosis, Allergic Bronchopulmonary, Allergic Bronchopulmonary, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Surgery, Mycetoma, Chronic Disease, Pulmonary Aspergillosis, business, Tomography, X-Ray Computed
Abstract

Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ∼240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include:Aspergillusnodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (Aspergillusinfection (microscopy or culture from biopsy) or an immunological response toAspergillusspp. and exclusion of alternative diagnoses, all present for at least 3 months.Aspergillusantibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferablyviavideo-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with singleAspergillusnodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up.

Published
2015

86. [Infectious diseases as a clinical specialty in Germany and Europe]

Author

Kern, Winfried V, Fätkenheuer, Gerd, Tacconelli, Evelina, and Ullmann, Andrew

Subjects
Cross Infection, Infectious Disease Medicine, rationale Antibiotikaverordnung, Drug Resistance, antibiotic stewardship, Drug Resistance, Microbial, Bacterial Infections, Continuing, healthcare quality, Infektiologie, ärztliche Weiterbildung, Education, Anti-Bacterial Agents, Europe, Microbial, Medical, Germany, Behandlungsqualität, Infectious diseases specialty, postgraduate training, Education, Medical, Continuing, Guideline Adherence, Humans, Specialization
Abstract

Clinical infectious diseases have only slowly been established as a medical specialty in Germany. The density of infectious diseases (ID) specialists and the number of ID divisions in general hospitals is still limited when compared with the situation in many other European countries, and there is also a lack of hospital-based medical microbiologists and infection control doctors for many reasons. Often, there is a lack of understanding of the roles and the performance of ID specialists versus microbiologists. Experience in other countries shows that ID specialists are important as clinical experts at the bedside, can help ascertain healthcare quality and patient safety, and are perfectly suited for undertaking strategic tasks in the field of cost-effective antimicrobial therapy algorithms and antibiotic stewardship (ABS) in hospitals. ID specialists are responsible for infection control in several countries, can improve the utility of diagnostic microbiology and are key partners in translational research. We estimate that more than 1,000 additional ID specialists are needed in this country, and believe that specially trained ABS experts can take over parts of their responsibilities and tasks in smaller hospitals. More capacity and flexibility in postgraduate training in infectious diseases, antibiotic stewardship and infection control in Germany will be critical to address the problem of antimicrobial resistance. (As supplied by publisher).

Published
2015

89. Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins

Author

Wurster, Sebastian, primary, Thielen, Vanessa, additional, Weis, Philipp, additional, Walther, Paul, additional, Elias, Johannes, additional, Waaga-Gasser, Ana Maria, additional, Dragan, Mariola, additional, Dandekar, Thomas, additional, Einsele, Hermann, additional, Löffler, Jürgen, additional, and Ullmann, Andrew J., additional

Published
2017
Full Text
View/download PDF

90. Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals

Author

Biehl, Lena M., primary, Bertz, Hartmut, additional, Bogner, Johannes, additional, Dobermann, Ute-Helke, additional, Kessel, Johanna, additional, Krämer, Carolin, additional, Lemmen, Sebastian, additional, von Lilienfeld-Toal, Marie, additional, Peter, Silke, additional, Pletz, Mathias W., additional, Rohde, Holger, additional, Schmiedel, Stefan, additional, Schubert, Sören, additional, Ullmann, Andrew J., additional, Fätkenheuer, Gerd, additional, and Vehreschild, Maria J. G. T., additional

Published
2017
Full Text
View/download PDF

91. Position paper on current aspects of sponsoring in accredited CME

Author

Stolz, Daiana, primary, Griebenow, Reinhard, additional, Tichelli, Andre, additional, Ullmann, Andrew J., additional, Costello, Richard W., additional, Michalis, Lampros, additional, Guenova, Margarita, additional, Sutter, Sandy, additional, De Andrade, Fabiola, additional, and Schaefer, Robert, additional

Published
2017
Full Text
View/download PDF

92. Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients

Author

Loeffler, Juergen, primary, Hafner, Julia, additional, Mengoli, Carlo, additional, Wirth, Clemens, additional, Heussel, Claus Peter, additional, Löffler, Claudia, additional, White, P. Lewis, additional, Ullmann, Andrew J., additional, Michel, Denise, additional, Wiegering, Verena, additional, Wölfl, Matthias, additional, Schlegel, Paul Gerhardt, additional, Einsele, Hermann, additional, Springer, Jan, additional, and Eyrich, Matthias, additional

Published
2017
Full Text
View/download PDF

93. The Epidemiology of Invasive Aspergillosis and Resistance Patterns of Aspergillus spp. in Germany - Interim Analysis of a Multicenter Observational Study

Author

Vehreschild, Maria J.G.T., Hamprecht, Axel, Adam, Thomas, Bader, Oliver, Becker, Caroline, Bekerdijan-Ding, Isabelle, Buchheidt, Dieter, Doelken, Gottfried, Elias, Johannes, Haase, Gerhard, Hahn-Ast, Corinna, Karthaus, Meinolf, Kekulé, Alexander, Krause, Stefan, Neumann, Silke, Keller, Peter, Kiehl, Michael, Rohde, Holger, La Rosée, Paul, Ruhnke, Markus, Schalk, Enrico, Schafhausen, Philippe, Schwartz, Stefan, Silling, Gerda, Schulz, Katrin, Staib, Peter, Ullmann, Andrew, Weber, Thomas, and Cornely, Oliver A.

Subjects
ddc: 610, 610 Medical sciences, Medicine, skin and connective tissue diseases
Abstract

Introduction: Reports on increasing identification of azole-resistant Aspergillus fumigatus in clinical and environmental isolates have raised concerns with respect to the frequency and clinical relevance of resistant Aspergillus spp. in hematological high-risk patient populations. Methods: In an[for full text, please go to the a.m. URL], Frühjahrstagung der Sektion Antimykotische Chemotherapie 2014

Published
2014

95. Hepatic Safety of Isavuconazole Compared With Voriconazole in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Complicated by Invasive Mold Disease: A Post-Hoc Analysis From the SECURE Study

Author

Heinz, Werner J., primary, Cornely, Oliver A., additional, Selleslag, Dominik, additional, Rahav, Galia, additional, Giladi, Michael, additional, Aoun, Mickael, additional, Herbrecht, Raoul, additional, Ullmann, Andrew J., additional, Azie, Nkechi, additional, Kovanda, Laura, additional, Kaufhold, Achim, additional, Engelhardt, Marc, additional, and Maertens, Johan, additional

Published
2016
Full Text
View/download PDF

96. Treatment of invasive fungal infections in cancer patients : updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver Andreas, Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew J., Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika

Subjects
ddc:610
Abstract

The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient’s risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.

Published
2013

98. Susceptibility of A. fumigatus‐specific T‐cell assays to pre‐analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes.

Author

Lauruschkat, Chris D., Wurster, Sebastian, Page, Lukas, Lazariotou, Maria, Dragan, Mariola, Weis, Philipp, Ullmann, Andrew J., Einsele, Hermann, and Löffler, Jürgen

Subjects
T cells, FLOW cytometry, ASPERGILLOSIS, CRYOPRESERVATION of cells, CYTOKINES
Abstract

Summary: Mould‐specific T cells detectable by flow cytometry or ELISPOT were proposed as a novel biomarker in invasive aspergillosis. To define protocols facilitating sample shipment and longitudinal analysis, this study evaluated the susceptibility of different functional assays for A. fumigatus‐specific T‐cell quantification and characterisation to pre‐analytic delays. PBMCs from 6 healthy donors were analysed after immediate isolation, after 6 hours whole blood storage or after cryopreservation using 3 different common media. Functional responses to A. fumigatus lysate stimulation were comparatively assessed by flow cytometry, ELISPOT and 14‐plex cytokine assay. After 6 hours pre‐analytic storage, all functional assays showed reduced detection rates, higher coefficients of variation (CV) and widely varying individual recovery indices of specific T‐cell response. While cryopreservation resulted in sufficient yields and largely unaltered cellular composition, outcomes of functional readouts significantly differed from freshly processed samples. For CD154‐based flow cytometry, only cryopreservation in RPMI supplemented with autologous serum resulted in satisfactory detection rates and CVs. For ELISPOT and cytokine secretion assays, none of the cryopreservation protocols provided sufficient concordance with immediately processed samples. Even using the same readout platform, individual analytes widely varied in their susceptibility to cryopreservation, highlighting that distinct optimisation is required depending on the downstream assay. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

99. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents.

Author

Decker, Christina, Wurster, Sebastian, Lazariotou, Maria, Hellmann, Anna-Maria, Einsele, Hermann, Ullmann, Andrew J, and Löffler, Jürgen

Abstract

Neutrophils are essential in the first line defense against moulds. This in vitro study assessed different neutrophil effector mechanisms in the presence of clinically relevant antifungal and immunosuppressive agents. Therapeutic concentrations of liposomal amphotericin B led to reduced IL-8 and oxidative burst response to the synthetic stimulus PMA, whereas no major alterations of oxidative burst, phagocytosis, or cytokine response to germinated stages of Aspergillus fumigatus and no supra-additive effects of antifungal and immunosuppressive drugs were observed. Conventional and liposomal amphotericin B as well as voriconazole, however, led to reduced neutrophil extracellular trap formation in response to A. fumigatus germ tubes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

100. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, and Ostermann, Helmut

Subjects
HEMATOLOGIC malignancies, COMMUNICABLE disease treatment, MYCOSES, ANTIFUNGAL agents, IMMUNOCOMPROMISED patients, AMPHOTERICIN B, NEUTROPENIA, ONCOLOGY, PATIENTS, PREVENTION, THERAPEUTICS, SOCIETIES, ACUTE myeloid leukemia treatment, MYELODYSPLASTIC syndromes treatment, HETEROCYCLIC compounds, VORICONAZOLE, CLINICAL trials, DRUG monitoring, HEMATOLOGY, HEMATOPOIETIC stem cell transplantation, MEDICAL societies, MYELODYSPLASTIC syndromes, PREVENTIVE health services, ACUTE myeloid leukemia
Abstract

Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT). Despite the development of new treatment options in the past decades, IFI remains a concern due to substantial morbidity and mortality in these patient populations. In addition, the increasing use of new immune modulating drugs in cancer therapy has opened an entirely new spectrum of at risk periods. Since the last edition of antifungal prophylaxis recommendations of the German Society for Haematology and Medical Oncology in 2014, seven clinical trials regarding antifungal prophylaxis in patients with haematological malignancies have been published, comprising 1227 patients. This update assesses the impact of this additional evidence and effective revisions. Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI). Posaconazole iv can be used when the oral route is contraindicated or not feasible. Intravenous liposomal amphotericin B did not significantly decrease IFI rates in acute lymphoblastic leukaemia (ALL) patients during induction chemotherapy, and there is poor evidence to recommend it for prophylaxis in these patients (CI). Despite substantial risk of IFI, we cannot provide a stronger recommendation for these patients. There is poor evidence regarding voriconazole prophylaxis in patients with neutropenia (CII). Therapeutic drug monitoring TDM should be performed within 2 to 5 days of initiating voriconazole prophylaxis and should be repeated in case of suspicious adverse events or of dose changes of interacting drugs (BIItu). General TDM during posaconazole prophylaxis is not recommended (CIItu), but may be helpful in cases of clinical failure such as breakthrough IFI for verification of compliance or absorption. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results